Read our Recent Headlines


Apr 16, 2014 by Dave Sobek

April 16 Biotech Update- An Early Continuation But Still a Fragile Sector

This is another slow day (in terms of news) and this time I promise to keep it short and actually keep it short as the sector is so volatile right.

Share 0 Comments Read more
Apr 15, 2014 by Dave Sobek

April 15 Biotech Update

Another day and nothing to talk about except more selling. There is really nothing more to say at this point that has not already been said. There is a significant.

Apr 14, 2014 by Dave Sobek

April 14 Biotech Update-

It was a really slow day on the news front, which could simply relate to the start of a pre-holiday week. I did not think it would extend all the.

Apr 14, 2014 by Joe Gantoss

IBB – Biotech Sector in The Despondency Point

iShares Nasdaq Biotechnology (IBB) - Nasdaq The best indicators for our biotech portfolios are the biotechnology indices IBB, NBI, XBI or XLV. We will maintain our focus on the IBB as.

Apr 11, 2014 by Tony Pelz

Catalyst Watch – Vol. 2, Edition 11 (4/11/14)

Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted),.

Apr 11, 2014 by Dave Sobek

April 11 Biotech Update- The Beating Continues

Well, there is not much to say about the market and sector other than selling is in vogue and there does not seem to be a clear catalyst that could.

Apr 09, 2014 by Dave Sobek

Celgene Markman Hearing Documents

Celgene Reply Markman Decl ISO Celgene Markman Reply-1 CELG brief Natco got RLI illegally blocks access to employee who got RLI fro Natco

More From All Reports

Introduction


Quick Facts

10

Analysts

500

Clients

22k

Followers

900

Reports

2.7k

Comments

5

Years

Overview

Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.


The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate. Subscribe to Chimera Research Group and proceed with confidence.

Get Started!


      Join      

 Learn More